Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer.

[1]  Ö. Türeci,et al.  Identification of neoantigens for individualized therapeutic cancer vaccines , 2022, Nature Reviews Drug Discovery.

[2]  A. Salvati,et al.  Comparison of the uptake mechanisms of zwitterionic and negatively-charged liposomes by HeLa cells. , 2020, Nanomedicine : nanotechnology, biology, and medicine.

[3]  D. Filippov,et al.  Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer , 2019, Oncoimmunology.

[4]  C. Löwik,et al.  Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles , 2019, Theranostics.

[5]  T. Doman,et al.  The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy , 2019, Clinical Cancer Research.

[6]  Wenbin Lin,et al.  Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy. , 2018, Angewandte Chemie.

[7]  Guimei Lin,et al.  Nanotechnology‐mediated immunochemotherapy combined with docetaxel and PD‐L1 antibody increase therapeutic effects and decrease systemic toxicity , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[9]  Guimei Lin,et al.  Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. , 2017, Acta biomaterialia.

[10]  Song Shen,et al.  Spatial Targeting of Tumor-Associated Macrophages and Tumor Cells with a pH-Sensitive Cluster Nanocarrier for Cancer Chemoimmunotherapy. , 2017, Nano letters.

[11]  E. Trafny,et al.  Physical properties and biological interactions of liposomes developed as a drug carrier in the field of regenerative medicine , 2017, Journal of liposome research.

[12]  Yung Chang,et al.  Surface charge-bias impact of amine-contained pseudozwitterionic biointerfaces on the human blood compatibility. , 2017, Colloids and surfaces. B, Biointerfaces.

[13]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[14]  Laura M Ensign,et al.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. , 2016, Advanced drug delivery reviews.

[15]  F. Ossendorp,et al.  Combinatorial prospects of nano-targeted chemoimmunotherapy. , 2016, Biomaterials.

[16]  L. Deangelis,et al.  Cancer-treatment-induced neurotoxicity—focus on newer treatments , 2016, Nature Reviews Clinical Oncology.

[17]  S. Vyas,et al.  A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery , 2015, Drug delivery.

[18]  Giulio Caracciolo,et al.  Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[19]  T. Ishida,et al.  Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma. , 2015, Biological & pharmaceutical bulletin.

[20]  Yang Yang,et al.  Nanoparticle-based immunotherapy for cancer. , 2015, ACS nano.

[21]  F. Ungaro,et al.  Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine inspired by combination therapy for cancer. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Can Zhang,et al.  Intracellular delivery and antitumor effects of pH-sensitive liposomes based on zwitterionic oligopeptide lipids. , 2013, Biomaterials.

[23]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[24]  L. Emens,et al.  Chemoimmunotherapy: reengineering tumor immunity , 2013, Cancer Immunology, Immunotherapy.

[25]  F. Hirsch,et al.  Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[27]  Dan Peer,et al.  Altering the immune response with lipid-based nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[28]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[29]  Ho-Keun Kwon,et al.  Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[30]  Giulio Caracciolo,et al.  DNA affects the composition of lipoplex protein corona: A proteomics approach , 2011, Proteomics.

[31]  Kazuo Maruyama,et al.  Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. , 2011, Advanced drug delivery reviews.

[32]  Laurence Zitvogel,et al.  Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.

[33]  Robert Langer,et al.  Nanotechnology in drug delivery and tissue engineering: from discovery to applications. , 2010, Nano letters.

[34]  L. Zitvogel,et al.  Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway , 2010, Clinical Cancer Research.

[35]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[36]  H. Pospisil,et al.  In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression , 2007, Investigational New Drugs.

[37]  F. Lokiec,et al.  Variations of soluble fas and cytokeratin 18-Asp 396 neo-epitope in different cancers during chemotherapy. , 2006, Anticancer research.

[38]  R. Steinman,et al.  Immunotherapy: Bewitched, Bothered, and Bewildered No More , 2004, Science.

[39]  P. Corrie.  Cytotoxic chemotherapy: clinical aspects , 2004 .

[40]  G. Peters,et al.  Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. , 2003, Biochemical pharmacology.

[41]  C. Blanke,et al.  Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma , 2000, Cancer.